June 2 (Reuters) - Bergenbio ASA:
* BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL
* STUDY IS FULLY FUNDED BY DHSC AND UKRI AND IS BEING MANAGED BY CLINICAL RESEARCH COMPANY IQVIA. DRUG MATERIAL AND OTHER TRIAL RESOURCES WILL BE PROVIDED BY BERGENBIO
* ANTICIPATES THAT TOP LINE DATA WILL READOUT LATER IN SUMMER Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Our Standards: The Thomson Reuters Trust Principles.